Microbix Biosystems Inc.

228 articles with Microbix Biosystems Inc.

• Microbix Presenting at Muskoka Capital Conference

  9/25/2019

  Meetings with Growth-Oriented Investors, September 27-29, 2019

• Microbix Quality Products Attain European Registration

  9/5/2019

  Four IVD Controls to Support Performance of Human Papilloma Virus Tests

• Microbix Reports Results for Q3 Fiscal 2019

  8/12/2019

  Microbix Biosystems Inc. reports results for its third quarter and nine months of fiscal 2019, the three-month and nine-month periods ending June 30, 2019 ("Q3" & "YTD"), with record YTD sales, strong YTD sales growth, improving percentage gross margin, and progress on its strategic goals.

• Microbix Provides Bioreactor Update

  8/1/2019

  Largest Customer Confirms Conversion Timetable & Provides Full-Scale Order

• FedDev Ontario Supports New Microbix Facility in Mississauga

  7/30/2019

  Contribution of $2.75 Million to Scale-up, Meet Demand, and Create Highly-Skilled Jobs

• Microbix Reports Results for Q2 Fiscal 2019

  5/13/2019

  Record Sales of $4.25 Million, Sales Growth of 42%, and Material Net Earnings

• Microbix to Present at Bloom Burton Conference

  4/26/2019

  Healthcare Investor Conference in Toronto on April 30 & May 1

• Microbix Announces Management Changes

  4/18/2019

  Ken Hughes Appointed COO, Kathryn Froh Retiring

• Microbix Announces Annual Meeting Voting Results

  3/28/2019

  Microbix Biosystems Inc., an innovator of biological products and technologies, announces the voting results from the Annual Meeting of Shareholders which was held on March 27, 2019.

• Microbix Announces Issuance of Stock Options - February 25, 2019

  2/25/2019

  Microbix Biosystems Inc., an innovator of biological products and technologies, announces the issuance of stock options under its shareholder-approved 2018 stock option plan, as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

• Microbix Reports Results for Q1 Fiscal 2019

  2/12/2019

  Microbix Biosystems Inc. reports results for its first quarter of fiscal 2019, the three-month period ending December 31, 2018 ("Q1"), with lower sales, improving percentage gross margin, improving and positive cash flow from operations and progress toward its operational goals.

• Microbix Provides Quality Assessment Products Update

  2/5/2019

  New Customers, More Products, and Expanding Capacity

• Microbix Enhances Quality Management System

  12/24/2018

  ISO 13485:2016 Medical Devices Certification Attained

• Microbix Wins Business Award of Excellence

  11/19/2018

  ​Recognized with 2018 Business Innovation Award by MBOT

• Microbix Exhibiting at MEDICA Trade Fair

  11/6/2018

  Showcasing Antigen and Quality Assessment Products

• Microbix to Present at Muskoka Capital Conference

  9/27/2018

  Conference Introduces Growth Companies to Investor September 28-30, 2018

• Microbix Reports Record Third Quarter Sales

  8/14/2018

  Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports financial results for its third quarter of fiscal 2018, the three-month period ending June 30, 2018 ("Q3"), with record sales and progress toward its operational goals.

• Microbix Reports Record First Quarter Sales

  2/14/2018

  Total Q1 revenue was $2,885,567, an increase of 48% compared to the first quarter of fiscal 2017.

• Microbix Expands Quality Assessment Product Family

  1/18/2018

• Microbix Reports Full Year and Fourth Quarter Results

  12/21/2017

  In 2017, the Company achieved a number of notable milestones, including attaining record sales of over $10 million.